: A Novel ROS1 Oncogenic Fusion Detected on Next Generation Sequencing.

Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40 fusion partners documented in the existing literature. Our report highlights a novel fusion partner of that has demonstrated a conclusive response to the current standard of treatment.